Chemomab Therapeutics (CMMB) Enterprise Value (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Enterprise Value came in at -$10.4 million in Q4 2025, up 27.34% YoY from -$8.1 million in Q4 2024, and down 3.08% on a QoQ basis from -$10.1 million in Q3 2025.
Chemomab Therapeutics (CMMB) Enterprise Value (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Enterprise Value data on file, last reported at -$10.4 million in Q4 2025.
- Quarterly Enterprise Value rose 27.34% year-over-year to -$10.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.4 million (up 27.34% YoY) and the FY2025 annual result came in at -$10.4 million, up 27.34% from the prior year.
- Enterprise Value slipped to -$10.4 million in Q4 2025, from -$10.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$9.5 million in Q2 2025 to a low of -$66.9 million in Q2 2021.
- A 5-year average of -$32.5 million and a median of -$24.1 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value plunged 849.59% — and 2023, when it surged 53.93%.
- Tracing CMMB's Enterprise Value over 5 years: stood at -$61.2 million in 2021, then jumped by 34.77% to -$39.9 million in 2022, then soared by 50.41% to -$19.8 million in 2023, then rose by 27.89% to -$14.3 million in 2024, then advanced by 27.34% to -$10.4 million in 2025.
- The last three Enterprise Value figures came in at -$10.4 million (Q4 2025), -$10.1 million (Q3 2025), and -$9.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.37 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -9.51 Mn |
| Mar 31, 2025 | -10.56 Mn |
| Dec 31, 2024 | -14.27 Mn |
| Sep 30, 2024 | -19.38 Mn |
| Jun 30, 2024 | -12.80 Mn |
| Mar 31, 2024 | -15.88 Mn |
| Dec 31, 2023 | -19.78 Mn |
| Sep 30, 2023 | -21.44 Mn |
| Jun 30, 2023 | -26.66 Mn |
| Mar 31, 2023 | -32.71 Mn |
| Dec 31, 2022 | -39.89 Mn |
| Sep 30, 2022 | -46.54 Mn |
| Jun 30, 2022 | -51.80 Mn |
| Mar 31, 2022 | -57.41 Mn |
| Dec 31, 2021 | -61.16 Mn |
| Sep 30, 2021 | -64.27 Mn |
| Jun 30, 2021 | -66.92 Mn |
| Mar 31, 2021 | -58.20 Mn |